Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | -22.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.57 | N/A | -22.84% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a commitment to advancing their pipeline despite current challenges. They remain focused on long-term goals.
Management highlighted ongoing efforts in research and development.
They emphasized the importance of maintaining operational stability during challenging times.
ACADIA PHARMACEUTICAL reported a loss that was worse than expected, which typically raises concerns among investors. However, the stock rose by 2.41%, indicating that investors may be optimistic about the company's long-term prospects despite the EPS miss. Management's focus on research and development could be a positive sign for future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 4, 2020